鼻咽癌的生物标志物。

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2025-03-19 DOI:10.1016/j.cca.2025.120257

Hsun-Ting Hsieh , Xin-Yao Zhang , Yi Wang , Xin-Qi Cheng

{"title":"鼻咽癌的生物标志物。","authors":"Hsun-Ting Hsieh , Xin-Yao Zhang , Yi Wang , Xin-Qi Cheng","doi":"10.1016/j.cca.2025.120257","DOIUrl":null,"url":null,"abstract":"<div><div>Nasopharyngeal Carcinoma (NPC) is a malignant tumor that is highly prevalent in Southeast Asia, particularly in China and Indonesia. According to the World Health Organization’s global cancer statistics in 2022, there were 120,434 new cases and 73,485 deaths from NPC. Risk factors contribute to NPC development including genetic factors, dietary habits, and Epstein-Barr virus (EBV) infection. This paper reviews the comparison of different types of EBV test for NPC over the last few years and summarized the performance of novel diagnostic biomarker such as newly reported EBV antibody, anti-BNLF2b IgG (P85-Ab), microRNAs, DNA methylation and other markers for detection of NPC. Because approximately 40% of NPC patients show negative EBV DNA levels, additional markers are needed for NPC diagnosis, especially in cases without EBV infection, to make the result trustworthy. The potential biomarkers including circulating tumor cells, proteins, microRNAs and Rta-IgG for prognostic and therapeutic effect also be summarized. This review provides insights into potential biomarkers for early NPC detection and diagnosis, which could lead to improved prevention, treatment, and prognosis strategies.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"572 ","pages":"Article 120257"},"PeriodicalIF":3.2000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Biomarkers for nasopharyngeal carcinoma\",\"authors\":\"Hsun-Ting Hsieh , Xin-Yao Zhang , Yi Wang , Xin-Qi Cheng\",\"doi\":\"10.1016/j.cca.2025.120257\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Nasopharyngeal Carcinoma (NPC) is a malignant tumor that is highly prevalent in Southeast Asia, particularly in China and Indonesia. According to the World Health Organization’s global cancer statistics in 2022, there were 120,434 new cases and 73,485 deaths from NPC. Risk factors contribute to NPC development including genetic factors, dietary habits, and Epstein-Barr virus (EBV) infection. This paper reviews the comparison of different types of EBV test for NPC over the last few years and summarized the performance of novel diagnostic biomarker such as newly reported EBV antibody, anti-BNLF2b IgG (P85-Ab), microRNAs, DNA methylation and other markers for detection of NPC. Because approximately 40% of NPC patients show negative EBV DNA levels, additional markers are needed for NPC diagnosis, especially in cases without EBV infection, to make the result trustworthy. The potential biomarkers including circulating tumor cells, proteins, microRNAs and Rta-IgG for prognostic and therapeutic effect also be summarized. This review provides insights into potential biomarkers for early NPC detection and diagnosis, which could lead to improved prevention, treatment, and prognosis strategies.</div></div>\",\"PeriodicalId\":10205,\"journal\":{\"name\":\"Clinica Chimica Acta\",\"volume\":\"572 \",\"pages\":\"Article 120257\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-03-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinica Chimica Acta\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0009898125001366\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898125001366","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

鼻咽癌（NPC）是一种恶性肿瘤，在东南亚非常普遍，特别是在中国和印度尼西亚。根据世界卫生组织公布的2022年全球癌症统计数据，全球有120434例新发病例，73485例死亡。影响鼻咽癌发展的危险因素包括遗传因素、饮食习惯和eb病毒感染。本文综述了近年来不同类型鼻咽癌EBV检测方法的比较，并对近年来新报道的EBV抗体、抗bnlf2b IgG （P85-Ab）、microrna、DNA甲基化等新型诊断标志物在鼻咽癌检测中的表现进行了综述。由于大约40%的鼻咽癌患者显示EBV DNA水平为阴性，因此鼻咽癌诊断需要额外的标记物，特别是在没有EBV感染的病例中，以使结果可信。综述了循环肿瘤细胞、蛋白、microrna和Rta-IgG等可能影响预后和治疗效果的生物标志物。这篇综述为鼻咽癌早期检测和诊断提供了潜在的生物标志物，可以改善预防、治疗和预后策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Biomarkers for nasopharyngeal carcinoma

Nasopharyngeal Carcinoma (NPC) is a malignant tumor that is highly prevalent in Southeast Asia, particularly in China and Indonesia. According to the World Health Organization’s global cancer statistics in 2022, there were 120,434 new cases and 73,485 deaths from NPC. Risk factors contribute to NPC development including genetic factors, dietary habits, and Epstein-Barr virus (EBV) infection. This paper reviews the comparison of different types of EBV test for NPC over the last few years and summarized the performance of novel diagnostic biomarker such as newly reported EBV antibody, anti-BNLF2b IgG (P85-Ab), microRNAs, DNA methylation and other markers for detection of NPC. Because approximately 40% of NPC patients show negative EBV DNA levels, additional markers are needed for NPC diagnosis, especially in cases without EBV infection, to make the result trustworthy. The potential biomarkers including circulating tumor cells, proteins, microRNAs and Rta-IgG for prognostic and therapeutic effect also be summarized. This review provides insights into potential biomarkers for early NPC detection and diagnosis, which could lead to improved prevention, treatment, and prognosis strategies.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.